Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Serum 25(OH)D showed no association with ALP (p = 0.114).

Source: 3.2. Associations Between Allopurinol and ALP. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were recruited by their nephrologists, and baseline demographic, clinical, and laboratory data were collected.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Allopurinol and Alkaline Phosphatase Levels in Patients with Non-Dialysis CKD

Study design awaiting verification · Journal of Clinical Medicine · 2026

Original publication title

Allopurinol and Alkaline Phosphatase Levels in Patients with Non-Dialysis CKD

Hulya Taskapan; Tolgay Taskapan; Antonio Bellasi; Paul Tam; Tabo Sikaneta

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Inhibition of xanthine oxidase with allopurinol increases bone alkaline phosphatase (ALP) in vitro, while ALP promotes bone and vascular mineralization and is linked to reduced survival in general and renal populations. However, clinical associations between allopurinol use and ALP have not yet been reported. We examined prospective associations between allopurinol use, ALP levels, and death in patients with non-dialysis CKD. Population and Setting: A total of 1636 multi-ethnic patients enrolled in the CAN AIM to PREVENT, a 3-year prospective observational study in Toronto, Canada. Primary Outcomes: ALP levels and the combination of renal and patient deaths. Statistical Analyses: Joint generalized structural equation modeling, causal mediation, and controlled direct effects.

Results:

Allopurinol use was associated with increased ALP (18.3% (95% CI: 10.9, 26.2, p < 0.001)) but not renal and patient death (HR = 1.32 (0.87, 1.99, p = 0.193)). The association between allopurinol and ALP was most pronounced when PTH and urate were low, and was partially mediated by PTH (7.9%, (p = 0.006)). Limitations: Observational and post hoc designs prevent causal inferences. Lack of data about specific ALP isoforms.

Conclusions:

Allopurinol use was associated with increased ALP but not renal or patient deaths in patients with non-dialysis CKD. Future studies can confirm the generalizability to other clinical populations and examine mechanisms and clinical significance.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Inhibition of xanthine oxidase with allopurinol increases bone alkaline phosphatase (ALP) in vitro, while ALP promotes bone and vascular mineralization and is linked to reduced survival in general and renal populations. However, clinical associations between allopurinol use and ALP have not yet been reported. We examined prospective associations between allopurinol use, ALP levels, and death in patients with non-dialysis CKD. Population and Setting: A total of 1636 multi-ethnic patients enrolled in the CAN AIM to PREVENT, a 3-year prospective observational study in Toronto, Canada. Primary Outcomes: ALP levels and the combination of renal and patient deaths. Statistical Analyses: Joint generalized structural equation modeling, causal mediation, and controlled direct effects.

Source: Background

Abstract: Results

Allopurinol use was associated with increased ALP (18.3% (95% CI: 10.9, 26.2, p < 0.001)) but not renal and patient death (HR = 1.32 (0.87, 1.99, p = 0.193)). The association between allopurinol and ALP was most pronounced when PTH and urate were low, and was partially mediated by PTH (7.9%, (p = 0.006)). Limitations: Observational and post hoc designs prevent causal inferences. Lack of data about specific ALP isoforms.

Source: Results

Abstract: Conclusions

Allopurinol use was associated with increased ALP but not renal or patient deaths in patients with non-dialysis CKD. Future studies can confirm the generalizability to other clinical populations and examine mechanisms and clinical significance.

Source: Conclusions
Authors’ abstract

Background:

Inhibition of xanthine oxidase with allopurinol increases bone alkaline phosphatase (ALP) in vitro, while ALP promotes bone and vascular mineralization and is linked to reduced survival in general and renal populations. However, clinical associations between allopurinol use and ALP have not yet been reported. We examined prospective associations between allopurinol use, ALP levels, and death in patients with non-dialysis CKD. Population and Setting: A total of 1636 multi-ethnic patients enrolled in the CAN AIM to PREVENT, a 3-year prospective observational study in Toronto, Canada. Primary Outcomes: ALP levels and the combination of renal and patient deaths. Statistical Analyses: Joint generalized structural equation modeling, causal mediation, and controlled direct effects.

Results:

Allopurinol use was associated with increased ALP (18.3% (95% CI: 10.9, 26.2, p < 0.001)) but not renal and patient death (HR = 1.32 (0.87, 1.99, p = 0.193)). The association between allopurinol and ALP was most pronounced when PTH and urate were low, and was partially mediated by PTH (7.9%, (p = 0.006)). Limitations: Observational and post hoc designs prevent causal inferences. Lack of data about specific ALP isoforms.

Conclusions:

Allopurinol use was associated with increased ALP but not renal or patient deaths in patients with non-dialysis CKD. Future studies can confirm the generalizability to other clinical populations and examine mechanisms and clinical significance.

Publication and source details

Original title: Allopurinol and Alkaline Phosphatase Levels in Patients with Non-Dialysis CKD

Hulya Taskapan; Tolgay Taskapan; Antonio Bellasi; Paul Tam; Tabo Sikaneta

Journal of Clinical Medicine · 2026

* Correspondence: hulyataskapan@yahoo.com (H.T.); tabosikaneta@yahoo.ca (T.S.)© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Janssen Inc.The CAN AIM to PREVENT was sponsored by Janssen Inc. which had no role in the design, conduct, or analysis of that or the current study.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:18:04.815510+00:00

DOI: 10.3390/jcm15124685 · PMC13302618